Exelixis Rides Strong Recovery: $66.28, $16.19B Market Cap & Strategic Partnerships Drive Cancer Drug Growth
Exelixis, a biotech leader in small‑molecule cancer drugs, shows strong Nasdaq growth, $16B cap, and strategic pharma partnerships fueling kidney, thyroid and melanoma therapies.
2 minutes to read
